MATEON’S PHASE 2 GLOBAL STUDY FOR OT-101/ TGF-β INHIBITOR AGAINST COVID-19 CLEARED FOR PATIENT ENROLLMENT IN ARGENTINA.

NEXT STORY
MediPharm Labs Initiates Clinical Trial for Use of Cannabis to Treat Chronic Kidney Disease Patients and Improve Quality of Life
PREV STORY
Syneos Health Named to Forbes 2020 List of World’s Best Employers
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Cynata Reports Positive 28-day Data From Cohort B of Phase 1 Trial of CYP-001 in GvHD

MELBOURNE, Australia, June 21, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine ...

author_avatar
NASDAQ Market News

East Bay Sports Medicine Joins Muir Orthopaedic Specialists

CONCORD, Calif., March 29, 2016 (GLOBE NEWSWIRE) -- East Bay Sports Medicine has joined ...

author_avatar
NASDAQ Market News

Dynavax Reports Second Quarter 2018 Financial Results

HEPLISAV-B® Launch Progressing as Planned with Key Customer Successes Three abstracts accepted for presentation ...

author_avatar
NASDAQ Market News